KAMPALA, Uganda, Oct. 20 /PRNewswire-FirstCall/ -- Pfizer Inc is pleased to announce its continued involvement and commitment to the Infectious Diseases Institute(IDI) which officially opens it doors today on the grounds of the Makerere University in Uganda. The fully operational facility will have major implications for patients and physicians in sub-Saharan Africa and fits well with Pfizer's other partnership and philanthropic programs around the globe.
Pfizer and the Pfizer Foundation have already contributed over $15 million USD to the establishment of the Infectious Diseases Institute.
Dr. McKinnell said, "The Infectious Diseases Institute marks a dramatic advance in addressing the public health needs of sub-Saharan Africa. As Pfizer, we are committed to improving the lives of people through partnerships such as this, our innovative products, the company's pipeline and various philanthropy initiatives around the globe."
Pfizer's Role in Establishing the IDI
* Pfizer has been instrumental in establishing the Academic Alliance for
AIDS Care and Prevention, recruiting other organizations to help
establish the IDI, and coordinating operational aspects of facility
construction and equipping.
* Pfizer has contributed a wide range of other resources to ensure the
program's success, including engineering and IT support, global
manufacturing support, legal services, procurement and shipping
services, donations of Pfizer's antifungal medicine Diflucan(R),
fundraising and organizational assistance, the skills and energy of
individual Pfizer employees such as the Global Health Fellows.
Editor's note: For a full program description of the IDI, see accompanying press release issued by the Infectious Diseases Society.
In addition to the IDI, Pfizer is involved in other public/private partnerships. In 2003, Pfizer's philanthropic efforts totalled nearly $700 million -- more than $2 million per day.
Pfizer's Global Philanthropy Programs
The Diflucan Partnership Program
* Diflucan is made available free of charge through government hospitals
and nongovernmental organizations to patients who are often lacking
even the most basic healthcare.
* Over 915 facilities in 23 countries have been involved in the program
to-date, treating over 87,000 patients for life-threatening fungal
* The Diflucan Partnership Program also trains healthcare workers -- more
than 18,000 healthcare providers to-date -- in partnership with the
International Association of Physicians in AIDS Care.
The Global Health Fellows Program
* The Fellows program, started in 2003, places Pfizer colleagues for up
to six months in fully paid assignments with NGOs and other
organizations to provide all levels of assistance in fighting the
* Fellows span the range of disciplines at Pfizer including
epidemiologists, physicians, IT experts and supply-chain coordinators.
The International HIV/AIDS Grants program
* Since 2002, the Pfizer Foundation has awarded $5 million to 40
* The grants focus on HIV training and capacity building in Caribbean,
African and Asian countries.
Southern HIV/AIDS Prevention Initiative
* The Pfizer Foundation started this Initiative in nine states in the
United States with rising rates of HIV infection (Florida, Georgia,
North Carolina, South Carolina, Texas, Tennessee, Mississippi, Alabama
* The Initiative funded 24 community-based organizations in 2003 and will
award additional grants over the next two years.
* Grants up to $50,000 per organization are designed to serve high
affected populations, such as multi-cultural women in low-income
The International Trachoma Initiative
* Pfizer Inc is dedicated to eliminating blinding trachoma, the world's
leading cause of preventable blindness.
* The effectiveness of a single annual dose of Zithromax in halting
infection has significantly accelerated progress toward elimination.
* ITI is currently active in eleven countries: Ethiopia, Ghana, Mali,
Mauritania, Morocco, Nepal, Niger, Senegal, Sudan, Tanzania, and
* To date, ITI has provided support for nearly 120,000 sight-saving
surgeries and distributed over 16.5 million antibiotic treatments.
Chuck Hardwick, head of the Pfizer Foundation and senior vice president, Pfizer Inc said, "Many people within Pfizer, with different expertise and skills, have put in a tremendous amount of time and effort to make today's IDI opening a reality. Their hard work, together with that of our esteemed partners, means that patients and their families stand to benefit from all of us working together."
Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiver orelectronic darkroom, PC or Macintosh, that can accept overhead transmissions.To retrieve a logo, please call 972-392-0888.